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a b s t r a c t
INTRODUCTION: Clostridium difﬁcile is the most common cause of healthcare-associated infections and
can have devastating morbidity and mortality. Traditional treatment algorithms involve intravenous
metronidazole and enteric metronidazole or vancomycin. Fidaxomicin (DiﬁcidR ) targets “switch regions”
within RNA polymerases and effectively kills clostridium difﬁcile bacteria and is typically administered
orally primarily or through a naso/oro-gastric conduit.
PRESENTATION OF CASE: 55-year-old with a recent elective surgical procedure was hospitalized with
multifocal pneumonia and subsequently developed clostridium difﬁcile colitis. This patient failed the
standard medical therapy for clostridium difﬁcile colitis, decompensated and required surgical exploration, partial colectomy and mucous ﬁstula creation. Following her surgery, her clinical condition
improved and her colitis resolved with the antegrade administration of ﬁdaxomicin through her mucous
ﬁstula.
DISCUSSION: Fidaxomicin is a newer to market therapeutic agent that has been shown to be effective in
the treatment of clostridium difﬁcile colitis. Previously studies have shown beneﬁt of oral ﬁdaxomicin
therapy for fulminant clostridium difﬁcile but our study case report describes the index case of topical
ﬁdaxomicin through a mucous ﬁstula.
CONCLUSION: In our case of fulminant clostridium difﬁcile colitis, Fidaxomicin administered in an antegrade fashion through a mucous ﬁstula may have reduced the need for total colectomy in the treatment
of fulminant clostridium difﬁcile colitis.
© 2017 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Clostridium difﬁcile (CD) is the most common cause of
healthcare-associated infections with over half a million cases
in the United States each year [1]. Oral ﬁdaxomicin (DiﬁcidR )
was approved by the FDA for the treatment of CD in 2011
and, in comparison to rectal vancomycin [2,3], it targets “switch
regions” within bacterial RNA polymerases. Fidaxomicin has been
shown to effectively neutralizes CD species producing symptomatic
cure and reduced recurrence. We present a case of fulminant
CD colitis following treatment for hospital acquired multifocal
pneumonia ultimately requiring an exploratory laparotomy and
segmental colectomy. Following segmental colectomy, the patient
was successfully treated with 10 days of antegrade ﬁdaxomicin
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administered through the mucus ﬁstula with subsequent stool
polymerase chain reaction (PCR) testing showing remission of disease. The work in this case has been reported in line with the SCARE
criteria [4].
2. Case report
A 55-year-old woman with a past medical history of hypertension, diabetes mellitus, prior transient ischemic attacks, and chronic
kidney disease was admitted to the ICU for altered mental status
after being found minimally responsive at home four postoperative
days following an elective panniculectomy. Her initial workup was
signiﬁcant for a multi-focal pneumonia with concomitant acute
kidney injury requiring initiation of hemodialysis. She was initially started on broad spectrum gram positive (vancomycin) and
gram negative (piperacillin-tazobactam) coverage but on hospital
day ten developed new onset watery diarrhea. Stool PCR testing
was positive for CD and the patient was started on intravenous
metronidazole (500 mg IV every six hours) and oral vancomycin
(250 mg every six hours). After six days and despite double ther-
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Fig. 1. Matured end ileostomy (A) and mucous ﬁstula (B) following segmental right colectomy for fulminant clostridium difﬁcile colitis. Note the presence of continued
pseudomembranous disease on the mucous ﬁstula prior to administration of antegrade ﬁdaxomicin.

apy, the patient’s disease progressed to fulminant CD colitis with
advanced imaging showing pancolitis without evidence of megacolon or perforation. Rectal vancomycin (500 mg every six hours)
and oral ﬁdaxomicin (200 mg twice daily) were added however
within two days the patient had decompensated, her leukocytosis
had progressed to 54,000/ul, and she required multiple vasoactive medications to sustain a mean arterial pressure greater than
65 mmHg. The decision was made to proceed to the operating room
for laparotomy and subtotal colectomy with an end ileostomy. The
procedure was performed by a general surgeon with more than
twenty years of experience with critical care surgery.
During laparotomy, the right colon appeared edematous with
evidence of signiﬁcant inﬂammation with a transition point to
healthy appearing colon distal to the hepatic ﬂexure. Similarly, the
small bowel appeared healthy proximal to the ileocecal valve. The
ascending colon and small bowel extending 10 cm proximal to the
ileocecal valve were resected leaving the patient in enteric discontinuity. The abdomen was then irrigated and a temporary abdominal
closure vacuum dressing was placed and the patient was taken
back to the ICU for continued resuscitation. While in the operating
room, the resected colon and small bowel were opened on the back
table revealing a signiﬁcant burden of pseudomembranous disease
within the ascending colon. Postoperative pathological analysis of
the resected colon and small bowel conﬁrmed our clinical suspicions identifying acute enterocolitis with transmural inﬂammation
and luminal pseudo-membrane formation.
The patient remained hemodynamically stable overnight and
was taken back to the operating room the following day for reevaluation of the abdomen and potential abdominal closure. On
second look, the terminal ileum and transverse colon appeared
healthy without progression of clinical colitis. The terminal ileum
and transverse colon stumps were externalized and matured following successful primary fascia closure (Fig. 1). Following the
second operation, the mucus ﬁstula developed new pseudomembranes consistent with persistent colitis. Over ten days, crushed
ﬁdaxomicin (200 mg twice daily) was administered through the
mucous ﬁstula by a red-rubber catheter in an antegrade fashion.
During the ten-day course of antegrade ﬁdaxomicin, the clinical burden of pseudomembranous disease on the mucous ﬁstula
receded, hemodynamic lability improved, and the leukocytosis
cleared. Upon completion of the ten-day course of antegrade ﬁdaxomicin by mucous ﬁstula, repeat stool CD PCR studies from the
mucous ﬁstula were negative for CD.

3. Discussion
Over the last decade, there has been a notable increase in the
severity of CD infections in addition to the discovery of new virulent strains [5]. With the high incidence and increased severity,
the literature has proposed multiple new agents and strategies for
managing CD infections that have failed to improve with metronidazole and vancomycin treatment alone [6]. Fidaxomicin was
approved by the FDA for the treatment of CD in 2011 after it was
shown to be non-inferior to rectal vancomycin in two large randomized controlled trials [7,8]. While most of these initial patients
only had mild to moderate illness, ﬁdaxomicin has proven efﬁcacy
for symptomatic cure in addition to reducing disease recurrence
compared to rectal vancomycin [3]. As a result, despite the higher
cost of ﬁdaxomicin, it has gained signiﬁcant popularity for complicated CD infections [9].
Fidaxomicin is currently FDA approved for oral administration
and has been demonstrated to have a 98–100% recovery when
crushed and dispersed into various liquid vehicles [10]. Furthermore, multiple case reports have demonstrated successful medical
management of severe CD colitis with crushed ﬁdaxomicin through
a nasogastric tube [11,12]. Since CD colitis is a toxin mediated disease, postoperative antibiotics are usually also recommended even
in the cases of subtotal colectomy which should in theory provide
mechanical source control [13]. Given the morbidity of a subtotal
colectomy, there has recently been a push towards bowel sparing treatment regimens, most notably being loop ileostomy with
intraoperative colonic lavage and 10 days of vancomycin antegrade
washes [14].
While the initial administration of oral ﬁdaxomicin in this case
did not prevent the need for surgical intervention, it is possible
that doses prior to surgery had not reached the affected colon secondary to the ileus from the patient’s inﬂammatory state. Following
segmental resection, topical administration of ﬁdaxomicin was
possible, bypassing any prior absorption or transit issues with oral
administration. Topical application of ﬁdaxomicin has rarely been
described in patients with severe disease requiring bowel resection. One prior case in the Czech Republic was described by Longin
et al. where topical ﬁdaxomicin 200 mg in small volume enemas
was started after the patient failed to improve with metronidazole
and vancomycin for eleven days after bowel resection. This patient
eventually tested negative for CD by NAAT ampliﬁcation and had
successful gastrointestinal tract restoration after ﬁve months [15].
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In this case, our patient failed to improve with intravenous
metronidazole and rectal vancomycin alone, prompting the addition of oral ﬁdaxomicin as a third agent for CD treatment. However,
when the patient became hypotensive and refractory to resuscitation, surgical intervention was required. After the creation of her
end-ileostomy and mucus ﬁstula, crushed ﬁdaxomicin successfully
supplemented enteric vancomycin resulting in symptomatic and
bacteriologic cure. This case report demonstrates a new administration route for ﬁdaxomicin through mucous ﬁstula that may
prove effective in curing fulminant CD colitis obviating the need
for subtotal colectomy.
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informed consent was obtained from the patient for publication of
this case report and accompanying images. A copy of the written
consent is available for review by the Editor-in-Chief of this journal
on request.
Author contribution
Arnot, Suzanne − Manuscript production, study design, data
analysis, patient care
Skancke, Matthew − Manuscript production, study design, data
analysis, patient care
Chen, Sheena − Study design, patient care
Abell, Bruce − Manuscript production, study design, data analysis, patient care

81

Guarantor
Matthew Skancke and Bruce Abell
References
[1] F.C. Lessa, C.V. Gould, L.C. McDonald, Current status of Clostridium difﬁcile
infection epidemiology, Clin. Infect. Dis. 55 (Suppl 2) (2012) S65–70, http://
dx.doi.org/10.1093/cid/cis319.
[2] A. Srivastava, M. Talaue, S. Liu, et al., New target for inhibition of bacterial
RNA polymerase: switch region, Curr. Opin. Microbiol. 14 (5) (2011) 532–543,
http://dx.doi.org/10.1016/j.mib.2011.07.030.
[3] R.L. Nelson, K.J. Suda, C.T. Evans, Antibiotic treatment for Clostridium
difﬁcile-associated diarrhoea in adults, Cochrane Database Syst. Rev. 3 (2017)
CD004610, http://dx.doi.org/10.1002/14651858.CD004610. pub5.
[4] R.A. Agha, A.J. Fowler, A. Saeta, et al., The SCARE Statement: Consensus-based
surgical case report guidelines, Int. J. Surg. 34 (2016) 180–186, http://dx.doi.
org/10.1016/j.ijsu.2016.08.014.
[5] P.R. Walters, B.S. Zuckerbraun, Clostridium difﬁcile infection: clinical
challenges and management strategies, Crit. Care Nurse 34 (4) (2014) 24–34,
http://dx.doi.org/10.4037/ccn2014822 (quiz 35).
[6] C. Fehér, A. Soriano, J. Mensa, A review of experimental and off-Label
therapies for clostridium difﬁcile infection, Infect Dis Ther 6 (1) (2017) 1–35,
http://dx.doi.org/10.1007/s40121-016-0140-z.
[7] T.J. Louie, M.A. Miller, K.M. Mullane, et al., Fidaxomicin versus vancomycin for
Clostridium difﬁcile infection, N. Engl. J. Med. 364 (5) (2011) 422–431, http://
dx.doi.org/10.1056/NEJMoa0910812.
[8] O.A. Cornely, D.W. Crook, R. Esposito, et al., Fidaxomicin versus vancomycin
for infection with Clostridium difﬁcile in Europe, Canada, and the USA: a
double-blind, non-inferiority, randomised controlled trial, Lancet Infect. Dis.
12 (4) (2012) 281–289, http://dx.doi.org/10.1016/S1473-3099(11)70374-7.
[9] C. Fehér, J. Mensa, A comparison of current guidelines of ﬁve international
societies on clostridium difﬁcile infection management, Infect. Dis. Ther. 5 (3)
(2016) 207–230, http://dx.doi.org/10.1007/s40121-016-0122-1.
®
[10] A. Tousseeva, J.D. Jackson, M. Redell, et al., Stability and recovery of DIFICID( )
(Fidaxomicin) 200-mg crushed tablet preparations from three delivery
vehicles, and administration of an aqueous dispersion via nasogastric tube,
Drugs R. D. 14 (4) (2014) 309–314, http://dx.doi.org/10.1007/s40268-0140067-3.
[11] E. Maseda, C. Hernandez-Gancedo, A. Lopez-Toﬁño, A. Suarez-de-la Rica, S.
Garcia-Bujalance, F. Gilsanz, Use of ﬁdaxomicin through a nasogastric tube for
the treatment of septic shock caused by Clostridium difﬁcile infection in a
patient with oral cancer admitted to the Surgical Critical Care Unit, Rev. Esp.
Quimioter. 26 (4) (2013) 375–377 http://www.ncbi.nlm.nih.gov/pubmed/
24399354.
[12] S. Arends, J. Defosse, C. Diaz, F. Wappler, S.G. Sakka, Successful treatment of
severe Clostridium difﬁcile infection by administration of crushed
ﬁdaxomicin via a nasogastric tube in a critically ill patient, Int. J. Infect. Dis. 55
(2017) 27–28, http://dx.doi.org/10.1016/j.ijid.2016.12.020.
[13] G.M. van der Wilden, M.P. Subramanian, Y. Chang, et al., Antibiotic regimen
after a total abdominal colectomy with ileostomy for fulminant clostridium
difﬁcile colitis: a multi-Institutional study, Surg. Infect. (Larchmt) 16 (4)
(2015) 455–460, http://dx.doi.org/10.1089/sur.2013.153.
[14] M.D. Neal, J.C. Alverdy, D.E. Hall, R.L. Simmons, B.S. Zuckerbraun, Diverting
loop ileostomy and colonic lavage: an alternative to total abdominal
colectomy for the treatment of severe, complicated Clostridium difﬁcile
associated disease, Ann. Surg. 254 (3) (2011) 423-7-9, http://dx.doi.org/10.
1097/SLA.0b013e31822ade48.
[15] A. Bilek, P. Longin, A. Melichar, M. Valeckova, Local application of ﬁdaxomicin
in a patient with subtotal colectomy following recurring Clostridium difﬁcile
infection, JMM Case Rep. 1 (1) (2014), http://dx.doi.org/10.1099/jmmcr.0.
001172.

Open Access
This article is published Open Access at sciencedirect.com. It is distributed under the IJSCR Supplemental terms and conditions, which
permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are
credited.

